Great West Life Assurance Co. Can Has $43.03 Million Position in Danaher Corporation (DHR)
Great West Life Assurance Co. Can lifted its holdings in Danaher Corporation (NYSE:DHR) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 506,887 shares of the conglomerate’s stock after purchasing an additional 11,914 shares during the period. Great West Life Assurance Co. Can owned 0.07% of Danaher worth $43,030,000 at the end of the most recent reporting period.
Other hedge funds have also added to or reduced their stakes in the company. ETRADE Capital Management LLC lifted its stake in shares of Danaher by 5.1% in the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares during the last quarter. Honeywell International Inc. acquired a new stake in shares of Danaher in the 2nd quarter valued at $25,317,000. Roundview Capital LLC lifted its stake in shares of Danaher by 2.0% in the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares during the last quarter. Eastern Bank raised its holdings in Danaher by 4,291.1% in the 2nd quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock worth $10,802,000 after acquiring an additional 125,086 shares during the period. Finally, Perkins Coie Trust Co raised its holdings in Danaher by 2.0% in the 2nd quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock worth $2,484,000 after acquiring an additional 586 shares during the period. 76.28% of the stock is owned by institutional investors and hedge funds.
In other news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Daniel L. Comas sold 88,184 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the transaction, the chief financial officer now owns 227,816 shares in the company, valued at approximately $20,735,812.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 273,810 shares of company stock worth $25,218,813. Insiders own 12.20% of the company’s stock.
Danaher (NYSE:DHR) last posted its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.05. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter in the previous year, the firm posted $0.87 EPS. The business’s revenue was up 9.6% compared to the same quarter last year. equities research analysts forecast that Danaher Corporation will post 3.99 earnings per share for the current year.
DHR has been the topic of several recent analyst reports. Jefferies Group reiterated a “buy” rating and issued a $95.00 target price on shares of Danaher in a report on Friday, August 4th. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a report on Thursday, October 5th. Cowen reiterated a “buy” rating and issued a $90.00 target price on shares of Danaher in a report on Wednesday, October 4th. Goldman Sachs Group reiterated a “neutral” rating and issued a $83.00 target price on shares of Danaher in a report on Tuesday, September 26th. Finally, Robert W. Baird lifted their target price on shares of Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Danaher currently has a consensus rating of “Buy” and a consensus price target of $93.31.
ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/02/great-west-life-assurance-co-can-has-43-03-million-position-in-danaher-corporation-dhr.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.